KALA BIO, Inc. Common Stock
KALAStock
$0.85−99.62%52W
Market Cap$16.66M
P/E—
Div yield—
Beta-2.49
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-106.36%
Price vs S&P 500 (4W)-67.79%
VGM Score27.52
Market Capitalization$16.66M
Earnings Surprise History
Q4 25-33.50est. -73.44
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KALAKALA BIO, Inc. Common Stock | C | — | F | $0.85 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Kala Bio is a clinical-stage biopharmaceutical company developing cell-derived therapies for rare eye diseases. The company's lead candidate, KPI-012, is a human mesenchymal stem cell product designed to restore corneal healing and treat severe retinal degenerative diseases including Retinitis Pigmentosa and Stargardt Disease. KPI-012 leverages multiple therapeutic factors including growth factors and neuroprotective proteins to address unmet needs in vision-threatening conditions.